Procren Depot 3.75 mg Nórsko - nórčina - Statens legemiddelverk

procren depot 3.75 mg

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

Procren Depot 30 mg Nórsko - nórčina - Statens legemiddelverk

procren depot 30 mg

abbvie as - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 30 mg

Risedronat Amneal 35 mg Nórsko - nórčina - Statens legemiddelverk

risedronat amneal 35 mg

amneal pharma europe limited - natriumrisedronat-2½-hydrat - tablett, filmdrasjert - 35 mg

Teceos 13 mg Nórsko - nórčina - Statens legemiddelverk

teceos 13 mg

cis bio international - butedronatetetranatrium - preparasjonssett til radioaktive legemidler - 13 mg

Libtayo Európska únia - nórčina - EMA (European Medicines Agency)

libtayo

regeneron ireland designated activity company (dac) - cemiplimab - karsinom, squamous cell - antineoplastiske midler - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Leuprorelinacetat Aurora Medical 3.75 mg Nórsko - nórčina - Statens legemiddelverk

leuprorelinacetat aurora medical 3.75 mg

2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 3.75 mg

Leuprorelinacetat Aurora Medical 11.25 mg Nórsko - nórčina - Statens legemiddelverk

leuprorelinacetat aurora medical 11.25 mg

2care4 aps - leuprorelinacetat - pulver og væske til injeksjonsvæske, suspensjon i tokammersprøyte - 11.25 mg

Binosto 70 mg Nórsko - nórčina - Statens legemiddelverk

binosto 70 mg

pharmaprim ab - alendronatnatriumtrihydrat - brusetablett - 70 mg

Tecfidera 240 mg Nórsko - nórčina - Statens legemiddelverk

tecfidera 240 mg

2care4 aps - dimetylfumarat - enterokapsel, hard - 240 mg

Tecfidera 240 mg Nórsko - nórčina - Statens legemiddelverk

tecfidera 240 mg

orifarm as - dimetylfumarat - enterokapsel, hard - 240 mg